Volume 46, Issue 2, Pages (August 2004)

Slides:



Advertisements
Similar presentations
The PSA Era is not Over for Prostate Cancer
Advertisements

Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection 
Volume 52, Issue 1, Pages (July 2007)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 63, Issue 5, Pages (May 2013)
Global Trends in Testicular Cancer Incidence and Mortality
Volume 46, Issue 3, Pages (September 2004)
Volume 61, Issue 5, Pages (May 2012)
Volume 50, Issue 5, Pages (November 2006)
Volume 53, Issue 5, Pages (May 2008)
Let the Games Begin (with EAU Approval)
Prostate Cancer Epidemic in Sight?
Volume 62, Issue 4, Pages (October 2012)
Volume 45, Issue 4, Pages (April 2004)
Volume 57, Issue 5, Pages (May 2010)
Daily Administration of Phosphodiesterase Type 5 Inhibitors for Urological and Nonurological Indications  Anthony J. Bella, Ling X. DeYoung, Mussa al-Numi,
Volume 52, Issue 1, Pages (July 2007)
Volume 50, Issue 1, Pages (July 2006)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey  John B. McKinlay, Carol L. Link  European.
Volume 51, Issue 1, Pages (January 2007)
Volume 54, Issue 4, Pages (October 2008)
Volume 73, Issue 2, Pages (February 2018)
Volume 46, Issue 6, Pages (December 2004)
Volume 62, Issue 3, Pages (September 2012)
Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka 
Volume 62, Issue 3, Pages (September 2012)
Volume 70, Issue 3, Pages (September 2016)
Prostate Cancer Detection: A View of the Future
Volume 51, Issue 2, Pages (February 2007)
Volume 56, Issue 2, Pages (August 2009)
Low-risk Prostate Cancer: Identification, Management, and Outcomes
Volume 68, Issue 1, Pages (July 2015)
Volume 64, Issue 4, Pages (October 2013)
Volume 60, Issue 1, Pages (July 2011)
Volume 72, Issue 3, Pages (September 2017)
Volume 54, Issue 2, Pages (August 2008)
Volume 49, Issue 6, Pages (June 2006)
Prostate Cancer Epidemic in Sight?
James N. Armitage, Stuart O. Irving, Neil A. Burgess  European Urology 
The PSA Era is not Over for Prostate Cancer
Volume 69, Issue 2, Pages (February 2016)
Volume 61, Issue 5, Pages (May 2012)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 53, Issue 2, Pages (February 2008)
Volume 53, Issue 6, Pages (June 2008)
Volume 53, Issue 6, Pages (June 2008)
Volume 66, Issue 2, Pages (August 2014)
Volume 57, Issue 5, Pages (May 2010)
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
The Inside-Out Transobturator Male Sling for the Surgical Treatment of Stress Urinary Incontinence After Radical Prostatectomy: Midterm Results of a Single-Center.
Volume 52, Issue 1, Pages (July 2007)
Volume 54, Issue 2, Pages (August 2008)
The Economic Costs of Overactive Bladder in Germany
Karl-Dietrich Sievert, Bastian Amend, Arnulf Stenzl  European Urology 
Volume 50, Issue 5, Pages (November 2006)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Testicular Cancer Variations in Time and Space in Europe
Volume 53, Issue 1, Pages (January 2008)
European Urology is “Your” Journal
The Start-Up of the Platinum Journal: A Fascinating Challenge
Volume 55, Issue 3, Pages (March 2009)
Understanding the Role of Botulinum Toxin A in the Treatment of the Overactive Bladder—More than Just Muscle Relaxation  Apostolos Apostolidis, Axel Haferkamp,
Volume 52, Issue 6, Pages (December 2007)
Volume 52, Issue 4, Pages (October 2007)
Proposed Mechanism for the Efficacy of Injected Botulinum Toxin in the Treatment of Human Detrusor Overactivity  Apostolos Apostolidis, Prokar Dasgupta,
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Epidemiology and Demographics of Prostatitis
Volume 54, Issue 1, Pages (July 2008)
Volume 51, Issue 5, Pages (May 2007)
Presentation transcript:

Volume 46, Issue 2, Pages 247-253 (August 2004) P2X3-Immunoreactive Nerve Fibres in Neurogenic Detrusor Overactivity and the Effect of Intravesical Resiniferatoxin  Ciaran M Brady, Apostolos Apostolidis, Yiangos Yiangou, Preston A Baecker, Anthony P Ford, Alex Freeman, Thomas S Jacques, Clare J Fowler, Praveen Anand  European Urology  Volume 46, Issue 2, Pages 247-253 (August 2004) DOI: 10.1016/j.eururo.2003.12.017

Fig. 1 Significant increase of mean density of P2X3-IR suburothelial nerve fibres in patients with NDO compared to controls (∗p=0.014). European Urology 2004 46, 247-253DOI: (10.1016/j.eururo.2003.12.017)

Fig. 2 Suburothelial nerve fibres stained for P2X3 in a biopsy from a NDO patient who responded to RTX, before (left) and after treatment (right). European Urology 2004 46, 247-253DOI: (10.1016/j.eururo.2003.12.017)

Fig. 3 A significant reduction (∗p=0.032) in the mean density of P2X3-IR suburothelial fibres was noticed following treatment in the 5 patients who responded to RTX, to values found in control tissues (a). No significant change in mean P2X3 suburothelial immunoreactivity was observed in non-responders (b). European Urology 2004 46, 247-253DOI: (10.1016/j.eururo.2003.12.017)